TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0

Reuters

2025/06/09

TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0

TAMPA, Fla., June 9, 2025 - TuHURA Biosciences, Inc. (NASDAQ:HURA), an innovative Phase 3 immune-oncology company, announced that the FDA has lifted the manufacturing-related partial clinical hold on its Phase 3 trial for IFx-2.0, aimed at treating advanced or metastatic Merkel cell carcinoma. This pivotal trial will now proceed under a Special Protocol Assessment Agreement with the FDA, evaluating IFx-2.0 alongside Keytruda® as a first-line treatment. The removal of the hold also unlocks the second tranche of funds from a $12.5 million PIPE financing, specifically providing TuHURA with an additional $2.23 million. This financial boost facilitates the initiation and activation of clinical sites across the United States, advancing TuHURA's mission to overcome resistance in cancer immunotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05232) on June 09, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2542810103"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542810103\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542810103?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-09 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542810103","market":"nz","top_or_hot":-1,"title":"TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TAMPA, Fla., June 9, 2025 - <a href=\"https://laohu8.com/S/HURA\">TuHURA Biosciences, Inc.</a> (NASDAQ:HURA), an innovative Phase 3 immune-oncology company, announced that the FDA has lifted the manufacturing-related partial clinical hold on its Phase 3 trial for IFx-2.0, aimed at treating advanced or metastatic Merkel cell carcinoma. This pivotal trial will now proceed under a Special Protocol Assessment Agreement with the FDA, evaluating IFx-2.0 alongside Keytruda® as a first-line treatment. The removal of the hold also unlocks the second tranche of funds from a $12.5 million PIPE financing, specifically providing TuHURA with an additional $2.23 million. This financial boost facilitates the initiation and activation of clinical sites across the United States, advancing TuHURA's mission to overcome resistance in cancer immunotherapy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05232) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-09 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TAMPA, Fla., June 9, 2025 - <a href=\"https://laohu8.com/S/HURA\">TuHURA Biosciences, Inc.</a> (NASDAQ:HURA), an innovative Phase 3 immune-oncology company, announced that the FDA has lifted the manufacturing-related partial clinical hold on its Phase 3 trial for IFx-2.0, aimed at treating advanced or metastatic Merkel cell carcinoma. This pivotal trial will now proceed under a Special Protocol Assessment Agreement with the FDA, evaluating IFx-2.0 alongside Keytruda® as a first-line treatment. The removal of the hold also unlocks the second tranche of funds from a $12.5 million PIPE financing, specifically providing TuHURA with an additional $2.23 million. This financial boost facilitates the initiation and activation of clinical sites across the United States, advancing TuHURA's mission to overcome resistance in cancer immunotherapy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05232) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HURA","symbol_name":"TuHURA Biosciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL9Vnkv2:1","article_id":"2542810103","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542810103","pubTimestamp":1749470454,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on June 09, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HURA":"TuHURA Biosciences, Inc.","BK4139":"生物科技"},"translate_title":"FDA解除IFX-2.0 3期试验的部分临床搁置后，TuHURA Biosciences获得了223万美元的额外资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HURA":0.9},"content_text":"TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0\n    \n\n        TAMPA, Fla., June 9, 2025 - TuHURA Biosciences, Inc. (NASDAQ:HURA), an innovative Phase 3 immune-oncology company, announced that the FDA has lifted the manufacturing-related partial clinical hold on its Phase 3 trial for IFx-2.0, aimed at treating advanced or metastatic Merkel cell carcinoma. This pivotal trial will now proceed under a Special Protocol Assessment Agreement with the FDA, evaluating IFx-2.0 alongside Keytruda® as a first-line treatment. The removal of the hold also unlocks the second tranche of funds from a $12.5 million PIPE financing, specifically providing TuHURA with an additional $2.23 million. This financial boost facilitates the initiation and activation of clinical sites across the United States, advancing TuHURA's mission to overcome resistance in cancer immunotherapy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05232) on June 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}